GlassScriptPhysician profile
Jill B Damico
NPI 1811950678
$6,691.64
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $1,652 · 2021: $2,630 · 2022: $1,588 · 2023: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $243.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,133.84 | 2019-2023 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $771.47 | 2019-2023 | Trulance, Xifaxan |
| Glaxosmithkline, LLC. | $767.36 | 2019-2022 | |
| Abbvie INC. | $536.63 | 2019-2023 | Ubrelvy |
| Amgen INC. | $498.56 | 2019-2022 | |
| Pfizer INC. | $451.76 | 2019-2022 | |
| Amarin Pharma, INC. | $449.35 | 2019-2022 | |
| Lilly USA, LLC | $394.90 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $347.14 | 2020-2023 | Synjardy, Jardiance |
| Astrazeneca Pharmaceuticals LP | $177.88 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $177.77 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $137.43 | 2020-2021 | |
| Radius Health, INC. | $97.36 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $81.30 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $80.86 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $71.23 | 2020-2023 | Eliquis |
| Astellas Pharma US INC | $55.54 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $51.35 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.10 | 2022 | |
| Sanofi-Aventis U.S. LLC | $50.85 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $45.36 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.66 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $35.01 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $34.35 | 2022 | |
| Sunovion Pharmaceuticals INC. | $30.77 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $28.69 | 2020 | |
| Alexion Pharmaceuticals, INC. | $22.79 | 2022 | |
| Avanir Pharmaceuticals, INC. | $16.44 | 2020 | |
| Gilead Sciences, INC. | $15.45 | 2020 | |
| Daiichi Sankyo INC. | $14.71 | 2019 | |
| Allergan, INC. | $14.17 | 2020 | |
| Nestle Healthcare Nutrition INC. | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Damico listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.